

August 1, 2012



Harris & Harris Group Notes Metabolon's Acquisition of Lipomics Technologies

NEW YORK, Aug. 1, 2012 (GLOBE NEWSWIRE) -- Harris & Harris Group, Inc. (Nasdaq:TINY), an early-stage, active investor in transformative nanotechnology companies, notes Metabolon's acquisition of Lipomics Technologies, Inc. This transaction combines Metabolon's metabolomics technology platform for commercial services and diagnostics with Lipomics' TrueMass® Profiling lipids technology platform. Lipomics' technology analyzes lipids, including metabolites of fatty acids, acylcarnitines, sterols, amino acids, bile acids and eicosanoids. The combined technologies expect to deliver new and improved diagnostic products and personalized medicine solutions for unmet needs, particularly in metabolic disease and cancer. The full press release can be viewed at <http://www.metabolon.com/news/PressReleases.aspx>.

Harris & Harris Group is an investor in Metabolon, Inc.

Detailed information about Harris & Harris Group and its holdings can be found on its website at www.HHVC.com.

This press release may contain statements of a forward-looking nature relating to future events. These forward-looking statements are subject to the inherent uncertainties in predicting future results and conditions. These statements reflect the Company's current beliefs, and a number of important factors could cause actual results to differ materially from those expressed in this press release. Please see the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2011, as well as subsequent filings, filed with the Securities and Exchange Commission for a more detailed discussion of the risks and uncertainties associated with the Company's business, including, but not limited to, the risks and uncertainties associated with venture capital investing and other significant factors that could affect the Company's actual results. Except as otherwise required by Federal securities laws, the Company undertakes no obligation to update or revise these forward-looking statements to reflect new events or uncertainties. The references to the websites www.HHVC.com and www.metabolon.com have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Harris & Harris Group is not responsible for the contents of third party websites.

CONTACT: DOUGLAS W. JAMISON
TEL. NO. (212) 582-0900

Source: Harris & Harris Group